Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …

Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …

Proteolysis-targeting chimeras (PROTACs) have been an area of intensive research with the
potential to extend drug space not target to traditional molecules. In the last half decade, we …

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated
oncogene in human cancers with mutations predominantly occurring in codon 12. These …

Proteolysis targeting chimera (PROTAC) technology represents a groundbreaking
development in drug discovery, leveraging the ubiquitin‒proteasome system to specifically …

Ferroptosis is an iron-dependent, non-apoptotic form of cell death involving in various
disease processes. Mechanistically, glutathione peroxidase 4 (GPX4) which belongs to the …

The phosphoinositide kinase PIKfyve has emerged as a new potential therapeutic target in
various cancers. However, limited clinical progress has been achieved with PIKfyve …

The transcriptional repressor B cell lymphoma 6 (BCL6) plays a critical role in driving
tumorigenesis of diffuse large B-cell lymphoma (DLBCL). However, the therapeutic potential …

Kristen rat sarcoma (KRAS) is one of the most common oncogenes in human cancers. As a
guanine nucleotide exchange factor, Son of Sevenless Homologue 1 (SOS1) represents a …

Abstract The Son of Sevenless 1 (SOS1) guanine nucleotide exchange factor, prevalent
across eukaryotic species, plays a pivotal role in facilitating the attachment of RAS protein to …